Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

August 31, 2020

Conditions
Gastrointestinal Stromal Tumor
Interventions
DRUG

regorafenib

Taken orally, once a day in the morning for 3 weeks followed by a one week rest period

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

97239

Oregon Health Sciences University, Portland

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Fox Chase Cancer Center

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

Bayer

INDUSTRY

lead

Suzanne George, MD

OTHER